AEGLEA BIOTHERAPEUTICS INC's ticker is AGLE and the CUSIP is 00773J103. A total of 56 filers reported holding AEGLEA BIOTHERAPEUTICS INC in Q3 2022. The put-call ratio across all filers is - and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2023 | $1,828,982 | +55.3% | 4,059,894 | 0.0% | 0.10% | +96.0% |
| Q1 2023 | $1,177,369 | -35.5% | 4,059,894 | 0.0% | 0.05% | -35.1% |
| Q4 2022 | $1,826,546 | -14.5% | 4,059,894 | 0.0% | 0.08% | -13.5% |
| Q3 2022 | $2,136,000 | +4.1% | 4,059,894 | 0.0% | 0.09% | +14.1% |
| Q2 2022 | $2,051,000 | -78.0% | 4,059,894 | 0.0% | 0.08% | -72.6% |
| Q1 2022 | $9,338,000 | -23.5% | 4,059,894 | +57.9% | 0.28% | +20.8% |
| Q4 2021 | $12,212,000 | -28.8% | 2,571,000 | +19.2% | 0.24% | -18.3% |
| Q3 2021 | $17,154,000 | +17.7% | 2,157,727 | +3.0% | 0.29% | +32.6% |
| Q2 2021 | $14,575,000 | +34.6% | 2,094,100 | +53.2% | 0.22% | +36.2% |
| Q1 2021 | $10,827,000 | +81.3% | 1,367,073 | +80.2% | 0.16% | +88.2% |
| Q4 2020 | $5,971,000 | +59.2% | 758,739 | +43.4% | 0.08% | +25.0% |
| Q3 2020 | $3,751,000 | +243.8% | 529,100 | +348.7% | 0.07% | +195.7% |
| Q2 2020 | $1,091,000 | – | 117,929 | – | 0.02% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| UNIVERSITY OF TEXAS/TEXAS AM INVESTMENT MANAGEMENT CO | 279,678 | $2,587,000 | 10.00% |
| Aisling Capital Management LP | 1,691,151 | $15,643,000 | 5.97% |
| Samsara BioCapital, LLC | 967,500 | $8,949,000 | 2.88% |
| Bain Capital Life Sciences Investors, LLC | 2,700,000 | $24,975,000 | 2.62% |
| Soleus Capital Management, L.P. | 369,852 | $3,421,000 | 1.95% |
| Nantahala Capital Management | 3,204,830 | $29,645,000 | 0.89% |
| Lion Point Capital, LP | 300,000 | $2,775,000 | 0.67% |
| Abingworth LLP | 240,500 | $2,221,000 | 0.62% |
| Sio Capital Management, LLC | 211,104 | $1,953,000 | 0.57% |
| Orbimed Advisors | 4,015,524 | $37,144,000 | 0.52% |